Walgreens reported total revenue of $36.4 billion in the fiscal third quarter, a 2.6% increase from the same period a year ago. This was driven by growth across its three business divisions, including its U.S. health-care unit which saw sales jump 7.6% compared with the same period a year ago.
Walgreens revised its profit guidance downwards due to a challenging environment for pharmacies and U.S. consumers, including softening consumer spending and reduced demand for COVID-19 vaccines. The company now expects fiscal 2024 adjusted earnings of $2.80 to $2.95 per share, down from its previous outlook of $3.20 to $3.35 per share.